CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer

Condition:   Squamous Cell Carcinoma of the Oral Cavity
Interventions:   Biological: Nivolumab, Surgery, Radiotherapy;   Biological: Nivolumab, Surgery, Chemoradiotherapy
Sponsors:   The Clatterbridge Cancer Centre NHS Foundation Trust;   University of Liverpool;   Bristol-Myers Squibb
Not yet recruiting

https://ift.tt/2PVgTKY